Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients.
| Autor: | Childress A; Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas, NV, USA., Sottile R; Kirk Kerkorian School of Medicine at UNLV, University of Nevada Las Vegas, Las Vegas, NV, USA., Khanbijian S; Kirk Kerkorian School of Medicine at UNLV, University of Nevada Las Vegas, Las Vegas, NV, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert review of neurotherapeutics [Expert Rev Neurother] 2023 Jul-Dec; Vol. 23 (11), pp. 945-953. Date of Electronic Publication: 2023 Oct 27. |
| DOI: | 10.1080/14737175.2023.2265068 |
| Abstrakt: | Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder with symptoms that may persist in up to 90% of adults diagnosed during childhood and continue to cause significant impairment throughout the lifespan. In the United States (US), amphetamine and methylphenidate formulations have been available to treat ADHD for several decades. Only one nonstimulant, atomoxetine, was available for the treatment of ADHD in adults until recently. In April 2022, a second nonstimulant, viloxazine extended-release (VLX-ER), became available in the US for the treatment of adult ADHD. Efficacy was previously established in placebo-controlled trials in children and adolescents. Areas Covered: VLX-ER is a norepinephrine reuptake inhibitor with serotonin activity. The efficacy in adults, adverse event profile, pharmacokinetics, drug-drug interactions, and metabolism of VLX-ER are reviewed. Expert Opinion: Despite the availability of effective pharmacological treatments for ADHD, many patients discontinue treatment in less than 1 year. Stimulants are effective in more than 80% of patients; however, some may have difficulty tolerating them. Although there were no head-to-head studies, the effect size of VLX-ER in an adult efficacy trial was lower than has been shown for stimulants. Nevertheless, the approval of VLX-ER adds another effective ADHD treatment option for adults. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|